Type 2 Diabetes
Conditions
Keywords
GLP-1 Receptor Agonists, DPP-4 inhibitors
Brief summary
The aim of this study is to detail the (mechanisms underlying the) actions of the GLP-1 receptor agonists and DPP-4 inhibitors on the cardiovascular, renal and gastrointestinal systems in patients with Type 2 Diabetes Mellitus.
Detailed description
GLP-1 receptors are present in most organ systems of the human body, and pharmacological interventions enhancing GLP-1 activity may influence the function of these organs. The use of GLP-1 receptor agonists (GLP-1RA) and DPP-4 inhibitors (DPP-4i) has been associated with an increased heart rate, acute pancreatitis and acute renal failure. To date, studies in humans detailing the effects of these drugs on these organ systems, biological processes and underlying mechanisms, which could explain these associations, are lacking. Therefore, as part of the EU-FP7 SAFEGUARD program, the present study will aim to detail the (mechanisms underlying the) actions of GLP-1RA and DPP-4i on the cardiovascular, renal and gastrointestinal system in healthy obese subjects and patients with T2DM. In the main study, sixty patients with type 2 diabetes will undergo two interventions within the same protocol in order to assess changes in the outcome parameters: * acute study = acute infusion with exenatide or placebo (to assess the cardiovascular and renal effects) * long-term study = 12 weeks of treatment with liraglutide, sitagliptin or placebo (to assess the cardiovascular, renal and gastrointestinal effects) In a substudy (termed 'acute MRI study'), twelve patients with type 2 diabetes will undergo an additional acute intervention study with exenatide (to assess the pancreatic effects) In a substudy (termed 'pilot-study'), ten healthy obese subjects will undergo a similar acute study like the patients with type 2 diabetes (to assess the cardiovascular and renal effects). Moreover, in these healthy subjects, the effects of exenatide during L-NMMA infusion will be assessed.
Interventions
DRUGLiraglutide
Liraglutide will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). If liraglutide is well tolerated it will be continued for 10 more weeks in a dosage of 1.8mg once daily.
DRUGSitagliptin
Sitagliptin 100mg will be given once daily for 12 weeks.
DRUGExenatide
Exenatide will be administered intravenously with a loading dose of 50ng/min for 30 minutes, followed by a maintenance dose of 25ng/min during the rest of the tests
Liraglutide-placebo will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). It will be continued for 10 more weeks in a dosage of 1.8mg once daily.
Sitagliptin-placebo be given once daily for 12 weeks.
Exenatide-placebo (saline) will be administered intravenously
DRUGL-NMMA
Sponsors
EU FP7: SAFEGUARD consortium
Amsterdam UMC, location VUmc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
35 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Age between 35 and 75 years. * Females must be post-menopausal (no menses \>1 year). * Type 2 diabetes (HbA1c 6.5-9% DCCT or 48-75 mmol/mol IFCC), who are being treated with a stable dose of oral antihyperglycemic agents (either metformin alone, SU alone or a combination of metformin and SU) for at least 3 months prior to inclusion. * BMI 25 - 40 kg/m2 * Caucasian * Signed informed consent
Exclusion criteria
* GFR \< 60 mL/min/1.73m2 * Current / chronic use of the following medication: thiazolidinediones, GLP-1RA, DPP-4i, glucocorticoids, NSAIDs, insulin, antimicrobial agents, chemotherapeutics or immune suppressants. Subjects on diuretics will only be excluded when these drugs (e.g. hydrochlorothiazide) cannot be stopped for the duration of the study. * History of or actual pancreatic disease or impaired pancreatic exocrine function * Active liver disease * History of or actual malignancy (with the exception of basal cell carcinoma) * Current urinary tract infection and active nephritis * Recent (\<6 months) history of cardiovascular disease, including acute coronary syndrome, stroke, transient ischemic neurologic disorder or chronic heart failure (New York Heart Association grade II-IV) * Current atrial fibrillation * Chronic infectious or auto-immune disease * Substance and/or alcohol abuse * History of allergy/hypersensitivity to any of the test agents * Complaints compatible with or established gastroparesis and/or neurogenic bladder * Any condition that has been recognized as a contra-indication for the use of GLP-1RA and DPP-4i, as listed in the respective SPCs * History of or actual (severe) mental illness * Inability to understand the study protocol and/or inability to give informed consent * History of claustrophobia or presence of metal objects/implants (because of MRI protocol) For the preceding Pilot study, we will include: * Males * Age between 18 and 50 years * BMI 25 - 40 kg/m2 * Caucasian The
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes from baseline following infusion of GLP-1RA (acute effects) and the changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on resting heart rate variability, as derived from electrocardiographic measurements. | 12 weeks |
| Changes from baseline following infusion of GLP-1RA (acute effects) and the changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on Glomerular Filtration Rate, measured by the inulin-clearance technique. | 12 weeks |
| Changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on pancreatic exocrine function, measured as fecal Elastase-1. | 12 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes from baseline following infusion of GLP-1RA (acute effects) and the changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on the following cardiovascular parameters: | 12 weeks | * Blood pressure and heart rate * Hemodynamic variables (blood pressure, heart rate, stroke volume, cardiac output/-index/-contractility, systemic vascular resistance) derived from non-invasive beat-to-beat finger blood pressure measurements * Cardiac autonomic nervous system function * Microvascular function and vasomotion * Arterial stiffness * Lipid spectrum * Glycemic variables (HbA1c, fasting and postprandial glucose) * Body anthropometrics: body weight, height, BMI and waist circumference * Body fat content |
| Changes from baseline following infusion of GLP-1RA (acute effects) and the changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on the following renal parameters: | 12 weeks | * Effective renal plasma flow (ERPF) * Renal tubular function * Renal damage, measured by urine biomarkers |
| Changes from baseline following infusion of GLP-1RA (acute effects*) and changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on the following gastrointestinal parameters: | 12 weeks | * Pancreatic exocrine function (\* In the acute intervention only exocrine pancreatic function is assessed) * Pancreatic structure * Pancreatic enzymes * Gallbladder emptying speed * Liver enzymes * Hepatic structure/steatosis * Gastric emptying |
Countries
Netherlands
Outcome results
None listed